Mesenchymal stem cells for neurological disorders
Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers
In this study, an onset time analysis was performed for the seven ocular adverse events (PTs) that remained positive in the sensitivity analysis
Retatrutide is a medication thats in testing made by Eli Lilly, the same manufacturer behind Zepbound
On average, patients lost about 40 pounds while on GLP-1 therapy
The first-line treatment for insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I), a research-based, highly effective approach
